✦ LIBER ✦
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
✍ Scribed by Mathias Witzens-Harig, Marie Luise Memmer, Martin Dreyling, Georg Hess
- Book ID
- 120680064
- Publisher
- BioMed Central
- Year
- 2013
- Tongue
- English
- Weight
- 171 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1471-2407
No coin nor oath required. For personal study only.